Catalyst Event
Exelixis Inc (EXEL) · Other
From KEDI Global Longevity Bio Index (KGLB)
5/30/2026, 12:00:00 AM
Exelixis announced positive results from a subgroup analysis of the Phase 3 CABINET pivotal trial, showing its drug CABOMETYX® significantly reduced the risk of disease progression or death in patients with advanced neuroendocrine tumors (NET). The data was presented at the 2026 ASCO Annual Meeting. This pivotal trial success is significant for biotech valuation and is estimated to have a high market impact (≥10%) expected
Korean Translation
엑셀리시스, 진행성 신경내분비종양(NET) 환자 대상 자사 약물 카보메틱스®(CABOMETYX®)가 질병 진행 또는 사망 위험을 크게 감소시켰다는 3상 CABINET 핵심 임상시험의 하위 그룹 분석 긍정적 결과 발표함. 해당 데이터는 2026년 미국임상종양학회(ASCO) 연례회의에서 발표되었으며, 이러한 핵심 임상 성공은 기업 가치 평가에 중대한 영향을 미치므로 높은 시장 영향(10% 이상)이 예상됨
Related Recent Events
Moderna Inc (MRNA) · Other
FDA Prescription Drug User Fee Act (PDUFA) target action date for a decision on the approval of the seasonal flu vaccine candidate (mRNA-1010) is scheduled for 2026-08-05, which is estimated to cause a ≥5% price impact scheduled.
8/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Pfizer Q2 2026 earnings release on 2026-08-04; Low importance estimated as it is a routine event, scheduled
8/4/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi is scheduled to release its Q2 2026 earnings results on July 30, 2026, expected.
7/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.
7/30/2026, 12:00:00 AM
GSK plc (GSK) · Earnings Release
GSK's second quarter 2026 earnings release scheduled. Routine earnings releases typically result in a price impact of approximately 1-3%.
7/28/2026, 12:00:00 AM
Revvity Inc (RVTY) · Earnings Release
Revvity's Q2 2026 earnings release is scheduled for 2026-07-27.
7/27/2026, 12:00:00 AM